PROTEIN, CORRESPONDING TO A MATURE REGION OF MORPHOGENETIC PROTEIN IN HUMAN MP-52, PHARMACEUTICAL COMPOSITION FOR TREATING OF CARTILAGE AND BONE DISEASES AND METHOD FOR PREPARING THEREOF
Eurasian Patent Organization Patent
Stats

Importance

EA Family Size
|
Non-US Coverage
|
Abstract
1. A protein, corresponding to a mature region of morphogenetic protein in human MP-52 having the following structure: Pro-Leu-Ala-Thr SEQ ID NO 1). 2. A homodimer protein according to Claim 1. 3. A pharmaceutical composition for treating cartilage and bone diseases comprising a therapeutically effective amount of the protein according to Claim 2 and a pharmaceutically acceptable carrier. 4. The pharmaceutical composition according to Claim 3 wherein cartilage and bone diseases are osteoarthritis or arthrosteitis. 5. The pharmaceutical composition according to Claim 3 wherein cartilage and bone diseases are osteoporosis. 6. The pharmaceutical composition according to Claim 3 wherein cartilage and bone diseases are bone fracture and bone defect. 7. The pharmaceutical composition according to Claim 3 wherein cartilage and bone diseases are radicular and arvecular defects. 8. A process for preparing the protein of Claim 1 which comprises culturing E. coli transformed with a plasmid containing DNA sequence ATG CCA CTA GCA ACT CGT CAG GGC AAG CGA CCC AGC AAG AAC CTT AAG GCT CGC TGC AGT CGG AAG GCA CTG CAT GTC AAG TTC AAG GAC ATG GGC TGG GAC GAC TGG ATC ATC GCA CCC CTT GAG TAC GAG GCT TTC CAC TGC GAG GGG CTG TGC GAG TTC CCA TTG CGC TCC CAC CTG GAG CCC ACG AAT CAT GCA GTC ATC CAG ACC CTG ATG AAC TCC ATG GAC CCC GAG TCC ACA CCA Pro Thr Cys Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe ATT GAC TCT GCC AAC AAC GTG GTG TAT AAG CAG TAT GAG GAC ATG GTC GTG GAG TCG TGT GGC TGC AGG, coding said protein with a methionine at the N-terminus, introducing the plasmid into E. Coli for transformation, solubilizing inclusion bodies obtained by culturing said E. Coli and purifying the monomer protein from the solubilized solution. 9. A process for preparing the dimer protein according to Claim 2 which comprises the steps of: constructing a plasmid containing DNA structure of which is defined in Claim 8; transforming E. coli by this plasmid culturing said E. coli, solubilizing inclusion bodies obtained by culturing said E. coli, purifying the monomer protein from the solubilized solution, refolding the monomer protein into a dimer protein and purifying the same. 10. A method for treating cartilage and bone diseases, which comprises administering to a human a pharmaceutical composition as claimed in Claim 3. 11. The method for treating cartilage and bone disease as claimed in Claim 11, wherein said disease is osteoarthritis or arthrosteitis. 12. The method for treating cartilage and bone diseases as claimed in Claim 11, wherein said disease is osteoporosis. 13. The method for treating cartilage and bone diseases as claimed in Claim 11, wherein said disease is bone fracture and bone defect. 14. The method for treating cartilage and bone diseases as claimed in Claim 11, wherein said disease is radicular and arvecular defects.

First Claim
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Country Designations

Patent Owner(s)
Patent Owner | Address |
---|---|
HOECHST MARION ROUSSEL LTD | JPTOKYO |
International Classification(s)

- [Classification Symbol]
- [Patents Count]
Inventor(s)
Inventor Name | Address |
---|---|
MAKISHIMA FUSAO | KAWAGOE-SHI SAITAMA 350-11 |
TAKAMATSU HIROYUKI | KOBE-SHI HYOGO 651-2271 |
MIKI HIDEO | KAWAGOE-SHI SAITAMA 350-11 |
KAWAI SHINJI | GIFU |
KIMURA MICHIO | TOKYO |
MATSUMOTO TOMOAKI | 〒2518501 神奈川県藤沢市鵠沼神明一丁目5番50号 日本精工株式会社内 KANAGAWA ?2518501 |
KATSUURA MIEKO | 2-14-2-106 SAKAE-CHO HIGASHIMURAYAMA-SHI TOKYO 189-0013 |
ENOMOTO KOICHI | TOKYO |
SATOH YUSUKE | TOYOTA-SHI 471-8571 |
Cited Art Landscape
- No Cited Art to Display

DATE PUBLISHED | PUBLICATION/PATENT NO. | PUBLICATION TYPE |
---|---|---|
December 29, 1999 |
EA,000582,B1
![]() |
PATENT |
April 30, 1998 |
EA,199700329,A1
![]() |
PATENT APPLICATION WITH SEARCH REPORT |
Full Text

Legal Events

Matter Detail

Renewals Detail

Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:

Add to additional portfolios:

Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement

Recipient Email Address

Recipient Email Address

Comment
Recipient Email Address

Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
Important Notes on Latency of Status data
This Status indicator is an estimation based on the relevant document kind code. As such, it status will only indicate "Published" or "Granted". Expired, lapsed or abandoned statuses are not available in this release. Please refer to the legal status information for more information.
This status should not be taken as legal conclusion. No representations are made as to the accuracy of the status provided. Please consult a legal professional before relying on this status information.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
Only for Granted EP cases
EP validations represent the countries in which the EP patent may be in force. Data is based on reporting from the various EP contracting states. The reporting consistency can vary across the countries.